Benchmark Reiterates Speculative Buy on Processa Pharma, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman reiterates a Speculative Buy rating on Processa Pharma (NASDAQ:PCSA) and maintains a $4 price target.
March 06, 2024 | 3:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Benchmark analyst reiterates Speculative Buy rating and maintains a $4 price target on Processa Pharma.
The reiteration of a Speculative Buy rating and the maintenance of a $4 price target by a Benchmark analyst could positively influence investor sentiment towards PCSA, potentially leading to an increase in its stock price in the short term. The specific mention of PCSA and the clear stance on its investment rating and price target provide a strong basis for this analysis.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100